Keywords
How to Cite
Abstract
Aim: to establish the dependence of cancer specific survival rate of patients with metastatic uveal melanoma on the treatment method, according to the Belarusian Cancer Registry.
Material and methods. We analyzed the data of the Belarusian cancer registry and medical records of patients diagnosed with metastatic uveal melanoma in the period from 2006 to 2015. Treatment methods included chemotherapy, radiation therapy, surgical removal of metastases, immunotherapy with roncoleukin. Hepatotropic therapy included hepatic artery chemoembolization, radiofrequency ablation of metastatic foci, or liver resection. We analyzed cancer specific 1-, 3-, 5- and 10-year survival of patients in treatment groups.
Results. The median cancer specific survival of patients who received only supportive care was 2.0 (95% CI 1.1–2.9) months, after any of the anticancer therapy methods application — 10.0 (95% CI 7.3–12.7) months. The median cancer specific survival in the chemotherapy group was 9.0 (95% CI 6.3–11.7) months, in the case of hepatotropic therapy — 20.0 (95% CI 10.9–29.1). The median cancer specific survival of patients receiving immunotherapy was 7.0 (95% CI 1.1–12.9), the survival plateau was reached after 48 months.
Conclusion. Metastatic uveal melanoma is characterized by a poor prognosis, including during therapy. Both hepatotropic and systemic therapy have limited efficacy. Further study of the tumor biology and immune microenvironment is required in order to determine possible targets of exposure.
References
Woodman SE. Metastatic uveal melanoma: biology and emerging treatments // Cancer J. 2012; 18(2):148–52. doi:10.1097/PPO.0b013e31824bd256
Singh AD, Turell ME, Topham AK. Uveal melanoma: trends in incidence, treatment, and survival // Ophthalmology. 2011;118(9):1881–5. doi:10.1016/j.ophtha.2011.01.040
Krishna Y, Acha-Sagredo A, Sabat-Pośpiech D et al. Transcriptome Profiling Reveals New Insights into the Immune Microenvironment and Upregulation of Novel Biomarkers in Metastatic Uveal Melanoma // Cancers (Basel). 2020;12(10):2832. doi:10.3390/cancers12102832
Martin M, Maßhöfer L, Temming P et al. Exome sequencing identifies recurrent somatic mutations in EIF1AX and SF3B1 in uveal melanoma with disomy 3 // Nat Genet. 2013;45(8):933–6. doi:10.1038/ng.2674
Jager MJ, Shields CL, Cebulla CM et al. Uveal melanoma // Nat Rev Dis Primers. 2020;6(1):24. doi:10.1038/s41572-020-0158-0
Melanoma: Uveal. NCCN Clinical Practice Guidelines in Oncology Version 1.2021 — April 08, 2021.
Bhatia S, Moon J, Margolin KA et al. Phase II trial of sorafenib in combination with carboplatin and paclitaxel in patients with metastatic uveal melanoma: SWOG S0512 // PLoS One. 2012;7(11):e48787. doi:10.1371/journal.pone.0048787
O'Neill PA, Butt M, Eswar CV et al. A prospective single arm phase II study of dacarbazine and treosulfan as first-line therapy in metastatic uveal melanoma // Melanoma Res. 2006;16(3):245–8. doi:10.1097/01.cmr.0000205017.38859.07
Schmidt-Hieber M, Schmittel A, Thiel E, Keilholz U. A phase II study of bendamustine chemotherapy as second-line treatment in metastatic uveal melanoma // Melanoma Res. 2004;14(6):439–42. doi:10.1097/00008390-200412000-00001
Carvajal RD, Piperno-Neumann S, Kapiteijn E et al. Selumetinib in Combination With Dacarbazine in Patients With Metastatic Uveal Melanoma: A Phase III, Multicenter, Randomized Trial (SUMIT) // J Clin Oncol. 2018;36(12):1232–1239. doi:10.1200/JCO.2017.74.1090
Algazi AP, Tsai KK, Shoushtari AN et al. Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies // Cancer. 2016;122(21):3344–3353. doi:10.1002/cncr.30258
Najjar YG, Navrazhina K, Ding F et al. Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study // J Immunother Cancer. 2020;8(1):e000331. doi:10.1136/jitc-2019-000331
Heppt MV, Steeb T, Gabriel Schlager J et al. Immune checkpoint blockade for unresectable or metastatic uveal melanoma: a systematic review // Cancer Treatment Reviews. 2017. doi:dx.doi.org/10.1016/j.ctrv
Mariani P, Piperno-Neumann S, Servois V et al. Surgical management of liver metastases from uveal melanoma: 16 years' experience at the Institut Curie // Eur J Surg Oncol. 2009;35(11):1192–7. doi:10.1016/j.ejso.2009.02.016
Nathan P, Cohen V, Coupland S et al. United Kingdom Uveal Melanoma Guideline Development Working Group. Uveal Melanoma UK National Guidelines // Eur J Cancer. 2015;51(16):2404–12. doi:10.1016/j.ejca.2015.07.013
Khoja L, Atenafu EG, Suciu S et al. Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: an international rare cancers initiative (IRCI) ocular melanoma study // Ann Oncol. 2019;30(8):1370–1380. doi:10.1093/annonc/mdz176
Schmittel A, Scheulen ME, Bechrakis NE et al. Phase II trial of cisplatin, gemcitabine and treosulfan in patients with metastatic uveal melanoma // Melanoma Res. 2005;15(3):205–7. doi:10.1097/00008390-200506000-00010
O'Neill PA, Butt M, Eswar CV et al. A prospective single arm phase II study of dacarbazine and treosulfan as first-line therapy in metastatic uveal melanoma // Melanoma Res. 2006;16(3):245–8. doi:10.1097/01.cmr.0000205017.38859.07
Kivelä T, Suciu S, Hansson J et al. Bleomycin, vincristine, lomustine and dacarbazine (BOLD) in combination with recombinant interferon alpha-2b for metastatic uveal melanoma // Eur J Cancer. 2003;39(8):1115–20. doi:10.1016/s0959-8049(03)00132-1
Bedikian AY, Papadopoulos N, Plager C et al. Phase II evaluation of temozolomide in metastatic choroidal melanoma // Melanoma Res. 2003;13(3):303–6. doi:10.1097/00008390-200306000-00013
Kivelä TT, Piperno-Neumann S, Desjardins L et al. Validation of a Prognostic Staging for Metastatic Uveal Melanoma: A Collaborative Study of the European Ophthalmic Oncology Group // Am J Ophthalmol. 2016;168:217–226. doi:10.1016/j.ajo.2016.06.002
Agarwala SS, Eggermont AM, O'Day S, Zager JS. Metastatic melanoma to the liver: a contemporary and comprehensive review of surgical, systemic, and regional therapeutic options // Cancer. 2014;120(6):781–9. doi:10.1002/cncr.28480
Emily N, Kinsey KS Salama Metastatic Uveal Melanoma—A Review of Current Therapies and Future Directions // Oncology & Hematology Review. 2017;13(2):100–6. doi:10.17925/OHR.2017.13.02.100
Breedis C, Young G. The blood supply of neoplasms in the liver // Am J Pathol. 1954;30(5):969–77
Vogl T, Eichler K, Zangos S et al. Preliminary experience with transarterial chemoembolization (TACE) in liver metastases of uveal malignant melanoma: local tumor control and survival // J Cancer Res Clin Oncol. 2007;133(3):177–84. doi:10.1007/s00432-006-0155-z
Huppert PE, Fierlbeck G, Pereira P et al. Transarterial chemoembolization of liver metastases in patients with uveal melanoma // Eur J Radiol. 2010;74(3):e38–44. doi:10.1016/j.ejrad.2009.03.064
Patel K, Sullivan K, Berd D et al. Chemoembolization of the hepatic artery with BCNU for metastatic uveal melanoma: results of a phase II study // Melanoma Res. 2005;15(4):297–304. doi:10.1097/00008390-200508000-00011
Hughes MS, Zager J, Faries M et al. Results of a Randomized Controlled Multicenter Phase III Trial of Percutaneous Hepatic Perfusion Compared with Best Available Care for Patients with Melanoma Liver Metastases // Ann Surg Oncol. 2016;23(4):1309–19. doi:10.1245/s10434-015-4968-3
Zimmer L, Vaubel J, Mohr P et al. Phase II DeCOG-study of ipilimumab in pretreated and treatment-naïve patients with metastatic uveal melanoma // PLoS One. 2015;10(3):e0118564. doi:10.1371/journal.pone.0118564
Algazi AP, Tsai KK, Shoushtari AN et al. Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies // Cancer. 2016;122(21):3344–3353. doi:10.1002/cncr.30258
Nathan P, Ascierto PA, Haanen J et al. Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172) // Eur J Cancer. 2019;119:168–178. doi:10.1016/j.ejca.2019.07.010
Piulats JM, Espinosa E, de la Cruz Merino L et al. Nivolumab Plus Ipilimumab for Treatment-Naïve Metastatic Uveal Melanoma: An Open-Label, Multicenter, Phase II Trial by the Spanish Multidisciplinary Melanoma Group (GEM-1402) // J Clin Oncol. 2021;39(6):586–598. doi:10.1200/JCO.20.00550
Pelster MS, Gruschkus SK, Bassett R et al. Nivolumab and Ipilimumab in Metastatic Uveal Melanoma: Results From a Single-Arm Phase II Study // J Clin Oncol. 2021;39(6):599–607. doi:10.1200/JCO.20.00605
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
© АННМО «Вопросы онкологии», Copyright (c) 2022